Pyoderma gangrenosum
Pyoderma gangrenosum е рядко възпалително кожно заболяване, при което болезнените пустули или възли се превръщат в язви, които прогресивно нарастват. Pyoderma gangrenosum не е инфекциозен. Лечението може да включва кортикостероиди, циклоспорин или различни моноклонални антитела. Въпреки че може да засегне хора от всякаква възраст, засяга най-вече хора на 40-те и 50-те години.
☆ В резултатите от Stiftung Warentest за 2022 г. в Германия, потребителското удовлетворение от ModelDerm е само малко по-ниско, отколкото при платените телемедицински консултации.
На крака на човек с улцерозен колит.
References
Pyoderma gangrenosum е рядко заболяване на кожата, което причинява болезнени язви с червени или лилави ръбове. Класифициран е като възпалително заболяване и е част от група, наречена неутрофилни дерматози. Причината за pyoderma gangrenosum е комплексна, включваща проблеми както с вродения, така и с адаптивния имунитет при хора, които са генетично предразположени. Наскоро изследователите се фокусираха върху космения фоликул като потенциална отправна точка на заболяването.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum е рядко кожно заболяване, причиняващо изключително болезнени язви. Въпреки че не разбираме напълно причината, знаем, че включва повишена активност на определени имунни клетки. Лечението на болестта все още не е лесно. Имаме различни лекарства, които потискат имунната система или променят нейната дейност. Наред с тях, ние също се фокусираме върху лечението на раните и управлението на болката. Кортикостероидите и циклоспоринът често са първият избор за лечение, но напоследък има повече изследвания за използването на биологични терапии като инхибитори на TNF-α. Тези биологични продукти са все по-предпочитани, особено при пациенти с други възпалителни състояния, и се използват по-рано в болестния процес.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
